Literature DB >> 25964141

Extracellular vesicles such as prostate cancer cell fragments as a fluid biopsy for prostate cancer.

S I Brett1, Y Kim2, C N Biggs2, J L Chin3, H S Leong1.   

Abstract

Extracellular vesicles (EVs) are cell-derived vesicles generated through a process of cell membrane shedding or storage vesicle release, as occurs during apoptosis, necrosis or exocytosis. Initially perceived as cellular by-products or 'dust' of insignificant biological importance, recent research has shed light on the role of EVs as mediators of intercellular communication, blood coagulation and disease progression. The prostate is a source of EVs and their abundance in complex biological fluids such as plasma, serum and urine make them compelling entities for a 'fluid biopsy'. As such, prostate cancer cell fragments (PCCF) are EVs generated by the tumor resident within the prostate and are also present in blood, expressing a portion of biomarkers representative of the primary tumor. High-throughput analytical techniques to determine biomarker expression on EVs is the last hurdle towards translating the full potential of prostate EVs for clinical use. We describe current state-of-the-art methods for the analysis of prostate-derived EVs in patient fluids such as plasma and the challenges that lie ahead in this emerging field of translational research.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25964141     DOI: 10.1038/pcan.2015.17

Source DB:  PubMed          Journal:  Prostate Cancer Prostatic Dis        ISSN: 1365-7852            Impact factor:   5.554


  98 in total

1.  Circulating tumour cells in prostate cancer patients receiving salvage radiotherapy.

Authors:  Lori E Lowes; Michael Lock; George Rodrigues; David D'Souza; Glenn Bauman; Belal Ahmad; Varagur Venkatesan; Alison L Allan; Tracy Sexton
Journal:  Clin Transl Oncol       Date:  2012-02       Impact factor: 3.405

2.  STEAP1 protein overexpression is an independent marker for biochemical recurrence in prostate carcinoma.

Authors:  Shadia M Ihlaseh-Catalano; Sandra A Drigo; Carlos M N de Jesus; Maria Aparecida C Domingues; José Carlos S Trindade Filho; João Lauro V de Camargo; Silvia R Rogatto
Journal:  Histopathology       Date:  2013-09-11       Impact factor: 5.087

3.  Activated platelets release two types of membrane vesicles: microvesicles by surface shedding and exosomes derived from exocytosis of multivesicular bodies and alpha-granules.

Authors:  H F Heijnen; A E Schiel; R Fijnheer; H J Geuze; J J Sixma
Journal:  Blood       Date:  1999-12-01       Impact factor: 22.113

4.  Vimentin exposed on activated platelets and platelet microparticles localizes vitronectin and plasminogen activator inhibitor complexes on their surface.

Authors:  Thomas J Podor; Davindra Singh; Paul Chindemi; Denise M Foulon; Robert McKelvie; Jeffrey I Weitz; Richard Austin; Ghislain Boudreau; Richard Davies
Journal:  J Biol Chem       Date:  2001-12-14       Impact factor: 5.157

Review 5.  Microvesicles as mediators of intercellular communication in cancer--the emerging science of cellular 'debris'.

Authors:  Tae Hoon Lee; Esterina D'Asti; Nathalie Magnus; Khalid Al-Nedawi; Brian Meehan; Janusz Rak
Journal:  Semin Immunopathol       Date:  2011-02-12       Impact factor: 9.623

6.  Cytometric characterization of circulating tumor cells captured by microfiltration and their correlation to the CellSearch(®) CTC test.

Authors:  Daniel L Adams; Steingrimur Stefansson; Christian Haudenschild; Stuart S Martin; Monica Charpentier; Saranya Chumsri; Massimo Cristofanilli; Cha-Mei Tang; R Katherine Alpaugh
Journal:  Cytometry A       Date:  2014-12-16       Impact factor: 4.355

Review 7.  Biomarkers for the diagnosis of new and recurrent prostate cancer.

Authors:  Girish Sardana; Eleftherios P Diamandis
Journal:  Biomark Med       Date:  2012-10       Impact factor: 2.851

8.  Find-me and eat-me signals in apoptotic cell clearance: progress and conundrums.

Authors:  Kodi S Ravichandran
Journal:  J Exp Med       Date:  2010-08-30       Impact factor: 14.307

9.  Proteomic profiling of exosomes leads to the identification of novel biomarkers for prostate cancer.

Authors:  Diederick Duijvesz; Kristin E Burnum-Johnson; Marina A Gritsenko; A Marije Hoogland; Mirella S Vredenbregt-van den Berg; Rob Willemsen; Theo Luider; Ljiljana Paša-Tolić; Guido Jenster
Journal:  PLoS One       Date:  2013-12-31       Impact factor: 3.240

10.  Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer.

Authors:  Johann S de Bono; Howard I Scher; R Bruce Montgomery; Christopher Parker; M Craig Miller; Henk Tissing; Gerald V Doyle; Leon W W M Terstappen; Kenneth J Pienta; Derek Raghavan
Journal:  Clin Cancer Res       Date:  2008-10-01       Impact factor: 12.531

View more
  2 in total

1.  Plasma Exosome Profiling of Cancer Patients by a Next Generation Systems Biology Approach.

Authors:  Valeriy Domenyuk; Zhenyu Zhong; Adam Stark; Nianqing Xiao; Heather A O'Neill; Xixi Wei; Jie Wang; Teresa T Tinder; Sonal Tonapi; Janet Duncan; Tassilo Hornung; Andrew Hunter; Mark R Miglarese; Joachim Schorr; David D Halbert; John Quackenbush; George Poste; Donald A Berry; Günter Mayer; Michael Famulok; David Spetzler
Journal:  Sci Rep       Date:  2017-02-20       Impact factor: 4.379

2.  Clinical significance of STEAP1 extracellular vesicles in prostate cancer.

Authors:  Karan Khanna; Nikki Salmond; Kalan S Lynn; Hon S Leong; Karla C Williams
Journal:  Prostate Cancer Prostatic Dis       Date:  2021-02-15       Impact factor: 5.554

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.